Krystal Biotech, Inc. - Common Stock (KRYS) stock analysis
KRYS · Krystal Biotech, Inc. - Common Stock
Latest recorded price: USD 297.90
Model-estimated fair value: USD 101.04. This assumption-based estimate is for general research and is not investment advice.
Sector and industry: Healthcare · Biotechnology
At $297.90, KRYS trades 194.8% above the model's base-case value of $101.04. Using Operating FCFF DCF (revenue x margin - reinvestment), the model estimates $85.48 in the conservative case and $118.93 in the optimistic case, with a valuation confidence score of 55/100. Fiscal 2025 figures: free cash flow margin 48.5%, ROIC 41.4%. The model does not flag any risk signals for this company.
Similar companies in Healthcare
- Kymera Therapeutics, Inc. - Common Stock (KYMR)
- Ligand Pharmaceuticals Incorporated - Common Stock (LGND)
- Madrigal Pharmaceuticals, Inc. - Common Stock (MDGL)
- MeiraGTx Holdings plc (MGTX)
- Mirum Pharmaceuticals, Inc. - common stock (MIRM)
- MannKind Corporation (MNKD)
- Moderna, Inc. (MRNA)
- Maravai LifeSciences Holdings, Inc. (MRVI)